ASTRAZEN

AstraZeneca Pharma India Limited

Biopharmaceuticals and oncology medicines distributor for AstraZeneca group

Healthcare›Healthcare›Pharmaceuticals & Biotechnology›Pharmaceuticals

astrazeneca.com(opens the company website in a new tab)
Ask AI

Key metrics

Price as of 2026-10-19

Stock price
₹6039.50
Market cap
15,099 Cr
Stock P/E
89.0
P/B
17.30
Dividend yield
0.5%
ROE (FY26)
21.5%
ROCE (FY26)
29.4%
Operating margin (FY26)
10.3%
OCF / EBITDA (FY26)
-5.8%
OCF / EBITDA (3Y)
20.4%

Full years shown; sign in free for the trailing twelve months. Learn about these metrics →

Price & valuation

Share price and valuation multiples (P/E, P/B and more) over time.

Loading price history…

Compare with peers

Loading peers…

What you need to know

AstraZeneca Pharma India is a science-led biopharmaceutical company that sells medicines in India in three therapy areas: Oncology, Biopharmaceuticals and Rare Disease.

Company snapshot

36thBy market cap

Ranked among 119 companies in Pharmaceuticals.

What we see

Positives
  • ✓Interest coverage of 52.0x — earnings comfortably cover interest obligations.
Concerns
  • ✗Only 20% of operating profit came in as cash over the last three years — much of it is tied up in unpaid bills or stock.
2 more signals from the filings.Sign in free to see them all

Statement tables · Standalone

Switches quarterly, P&L, balance sheet, and cash flow. Key metrics and ratios stay on consolidated when available.

Standalone only

Amounts in ₹ Cr · tap + to expand rows

Quarterly results

Quarterly · ₹ Cr · tap + rows to expand

MetricSept 2023Dec 2023Mar 2024Jun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Sales311 Cr306 Cr383 Cr388 Cr408 Cr440 Cr480 Cr526 Cr559 Cr612 Cr579 Cr683 Cr
Operating expenses (approx.)258 Cr291 Cr334 Cr349 Cr355 Cr363 Cr394 Cr445 Cr484 Cr567 Cr518 Cr634 Cr
EBITDA53 Cr15 Cr49 Cr38 Cr53 Cr77 Cr86 Cr81 Cr75 Cr45 Cr61 Cr49 Cr
OPM %17.0%4.9%12.9%9.8%12.9%17.5%18.0%15.4%13.4%7.3%10.5%7.2%
Other income8 Cr10 Cr9 Cr8 Cr8 Cr8 Cr16 Cr11 Cr6 Cr5 Cr6 Cr9 Cr
Interest0.50 Cr0.61 Cr-0.07 Cr0.11 Cr0.34 Cr0.33 Cr0.68 Cr0.72 Cr0.67 Cr1 Cr2 Cr2 Cr
Depreciation4 Cr4 Cr4 Cr4 Cr9 Cr9 Cr18 Cr17 Cr3 Cr4 Cr6 Cr5 Cr
Profit before tax73 Cr20 Cr54 Cr-15 Cr51 Cr42 Cr78 Cr75 Cr73 Cr47 Cr58 Cr51 Cr
Tax %28.6%22.5%27.4%22.2%24.7%26.6%25.8%25.3%25.5%30.0%22.8%25.3%
Net profit52 Cr16 Cr39 Cr-12 Cr38 Cr31 Cr58 Cr56 Cr54 Cr33 Cr45 Cr38 Cr
EPS (₹)₹20.95₹6.32₹15.79₹-4.72₹15.37₹12.34₹23.30₹22.33₹21.69₹13.04₹17.95₹15.17

Profit & loss (annual)

Annual · last column is TTM · ₹ Cr · tap + to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales549 Cr572 Cr728 Cr832 Cr814 Cr806 Cr1,003 Cr1,296 Cr1,716 Cr2,276 CrSign in free for the trailing twelve months
Operating expenses (approx.)512 Cr526 Cr657 Cr711 Cr678 Cr719 Cr838 Cr1,111 Cr1,462 Cr2,014 CrSign in free for the trailing twelve months
EBITDA37 Cr46 Cr71 Cr121 Cr135 Cr86 Cr165 Cr184 Cr254 Cr262 CrSign in free for the trailing twelve months
OPM %6.7%8.1%9.8%14.5%16.7%10.7%16.5%14.2%14.8%11.5%Sign in free for the trailing twelve months
Other income14 Cr12 Cr16 Cr13 Cr13 Cr15 Cr26 Cr35 Cr41 Cr28 CrSign in free for the trailing twelve months
Interest——0 Cr1 Cr1 Cr0.95 Cr0.63 Cr1 Cr1 Cr4 CrSign in free for the trailing twelve months
Depreciation16 Cr15 Cr15 Cr19 Cr20 Cr17 Cr16 Cr15 Cr40 Cr29 CrSign in free for the trailing twelve months
Profit before tax36 Cr44 Cr73 Cr114 Cr127 Cr83 Cr134 Cr220 Cr156 Cr252 CrSign in free for the trailing twelve months
Tax %43.5%40.8%25.1%36.6%26.6%25.8%26.0%26.4%26.0%25.6%Sign in free for the trailing twelve months
Net profit20 Cr26 Cr54 Cr72 Cr93 Cr62 Cr99 Cr162 Cr116 Cr188 CrSign in free for the trailing twelve months
EPS (₹)₹8.00₹10.40₹21.78₹28.88₹37.32₹24.64₹39.72₹64.60₹46.30₹75.01Sign in free for the trailing twelve months
Dividend payout %————5.4%8.1%20.1%24.8%51.8%42.7%Sign in free for the trailing twelve months
Sign in free for the trailing twelve months

The latest four quarters added up, next to each full year

Balance sheet

Annual · ₹ Cr · tap + rows to expand

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity capital5 Cr5 Cr5 Cr5 Cr5 Cr5 Cr5 Cr5 Cr5 Cr5 Cr
Reserves218 Cr242 Cr296 Cr359 Cr451 Cr506 Cr584 Cr707 Cr765 Cr868 Cr
Borrowings——————————
Other liabilities193 Cr214 Cr261 Cr342 Cr319 Cr345 Cr396 Cr366 Cr748 Cr1,116 Cr
Total liabilities415 Cr461 Cr562 Cr706 Cr775 Cr857 Cr985 Cr1,078 Cr1,518 Cr1,989 Cr
Fixed assets (net)87 Cr75 Cr75 Cr72 Cr81 Cr74 Cr69 Cr60 Cr64 Cr117 Cr
CWIP5 Cr4 Cr7 Cr24 Cr4 Cr2 Cr1 Cr0.27 Cr0 Cr0 Cr
Investments——0 Cr0 Cr0 Cr0 Cr0 Cr57 Cr0 Cr0 Cr
Loans & advances——0.81 Cr0.80 Cr0.36 Cr0.09 Cr0.08 Cr0.13 Cr0.30 Cr0 Cr
Inventories58 Cr113 Cr118 Cr165 Cr160 Cr140 Cr190 Cr228 Cr549 Cr1,027 Cr
Trade receivables43 Cr55 Cr80 Cr83 Cr85 Cr86 Cr108 Cr153 Cr185 Cr214 Cr
Cash & bank115 Cr114 Cr173 Cr84 Cr352 Cr448 Cr500 Cr506 Cr536 Cr448 Cr
Other assets109 Cr100 Cr108 Cr278 Cr92 Cr105 Cr117 Cr74 Cr185 Cr183 Cr
Total assets415 Cr461 Cr562 Cr706 Cr775 Cr857 Cr985 Cr1,078 Cr1,518 Cr1,989 Cr

Cash flows

Annual · ₹ Cr · tap + rows to expand · last column includes FCF

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Cash from operating activity38 Cr9 Cr55 Cr87 Cr105 Cr101 Cr58 Cr93 Cr65 Cr-15 Cr
Cash from investing0.25 Cr-9 Cr4 Cr-171 Cr173 Cr5 Cr18 Cr22 Cr31 Cr19 Cr
Cash from financing0 Cr0 Cr0 Cr-6 Cr-9 Cr-9 Cr-24 Cr-44 Cr-66 Cr-92 Cr
Net cash flow38 Cr-0.57 Cr59 Cr-90 Cr269 Cr96 Cr52 Cr70 Cr31 Cr-88 Cr
Free cash flow (OCF − Capex)32 Cr3 Cr36 Cr73 Cr97 Cr91 Cr50 Cr82 Cr64 Cr-19 Cr

Ratios

MetricMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %15.9%17.7%24.2%31.6%28.1%16.4%22.9%31.0%20.5%29.4%
ROE %9.0%10.5%18.1%19.8%20.5%12.0%16.9%22.7%15.0%21.5%
Debtor days29354037383939433934
Inventory days1499147768685959857082164569539404
Days payable22781245977109066876498356157830021
Cash conversion cycle-750267-251-195-31-156-1231271569417
OCF / EBITDA %103.1%19.0%77.1%72.4%77.3%117.0%35.3%50.2%25.7%-5.8%
OCF / EBITDA % (3 years)——65.9%63.4%75.5%85.6%68.2%57.7%35.8%20.4%
Debt / equity——————0.02———
Current ratio1.321.551.741.812.202.282.312.611.911.76
Net debt / EBITDA-3.10-2.46-2.43-0.69-2.60-5.20-3.03-2.74-2.11-1.71